News & Updates
Showing Multidisciplinary articles
Showing
Viral load, ART regimen predict mortality in infants born to mothers living with HIV
Several infants born to mothers living with HIV die within 50 weeks, and some of the factors that may contribute to infant death include lower maternal CD4 count, higher viral load, and maternal antiretroviral (ART) regimen, among others, suggests a study presented at CROI 2026.
Viral load, ART regimen predict mortality in infants born to mothers living with HIV
18 Mar 2026
Enfortumab vedotin plus pembrolizumab extends survival in MIBC
In patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy, neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab elicits improvements in event-free survival (EFS), overall survival (OS), and pathological complete response (pCR) rate relative to neoadjuvant gemcitabine plus cisplatin, according to the phase III KEYNOTE-B15 study.
Enfortumab vedotin plus pembrolizumab extends survival in MIBC
17 Mar 2026
HK study: START-FIT strategy using STRIDE regimen promising in HCC
Sequential transarterial chemoembolization, stereotactic body radiotherapy, and immunotherapy (START-FIT) using the STRIDE regimen of single-dose tremelimumab plus regular-interval durvalumab offers promising efficacy and is well tolerated in patients with locally advanced, unresectable hepatocellular carcinoma (HCC), a single-arm, multicentre, phase II study in Hong Kong has shown.
